LON:MXC Argent BioPharma (MXC) Share Price, News & Analysis GBX 22 +1.00 (+4.76%) (As of 04/3/2024) Add Compare Share Share Stock Analysis Stock AnalysisHeadlines About Argent BioPharma Stock (LON:MXC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Argent BioPharma alerts:Sign Up Key Stats Today's Range 22▼ 2250-Day Range 22▼ 2252-Week Range 13.10▼ 600Volume264 shsAverage Volume26,353 shsMarket Capitalization£9.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. In addition, the company provides Irnican that is in preclinical phase for the tetrahydrocannabinol, as well as offers ArtemiC and non-pharma products. Further, it offers consulting services, including clinical research services. MGC Pharmaceuticals Limited was founded in 2014 and is based in Subiaco, Australia.Read More… WARNING: “Buffett Indicator” flashing for first time in 50 years (Ad)The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.Take these 4 steps today to protect your retirement NOW Receive MXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Argent BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address MXC Stock News HeadlinesArgent BioPharma Ltd (RGT)May 9, 2024 | investing.comArgent BioPharma starts trading on OTCQB Venture Market; appoints CFOMay 6, 2024 | au.investing.comElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.October 21, 2024 | Porter & Company (Ad)Argent BioPharma appoints Dr Shlomo Sadoun to advisory boardApril 14, 2024 | au.investing.comMGC Pharmaceuticals Ltd (MXC)January 30, 2024 | uk.investing.comMGC Pharmaceuticals raising additional US$500,000 via private placementDecember 22, 2023 | au.investing.comMGC Pharmaceuticals Ltd MXCDecember 20, 2023 | morningstar.comMGC Pharma receives Saudi approval for ArtemiCDecember 19, 2023 | au.investing.comSee More Headlines MXC Stock Analysis - Frequently Asked Questions How have MXC shares performed this year? Argent BioPharma's stock was trading at GBX 27 on January 1st, 2024. Since then, MXC shares have decreased by 18.5% and is now trading at GBX 22. View the best growth stocks for 2024 here. How do I buy shares of Argent BioPharma? Shares of MXC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Argent BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Argent BioPharma investors own include Rolls-Royce Holdings plc (RR), Argo Blockchain (ARB), AutoZone (AZO), BP (BP), Chaarat Gold (CGH), Diageo (DGE) and EQTEC (EQT). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPetroleum And Natural Gas Current SymbolLON:MXC CUSIPN/A CIKN/A Webmgcpharma.com.au Phone61-8-6555-2950FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-17,020,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-58.96% Debt Debt-to-Equity Ratio1,436.12 Current Ratio0.75 Quick RatioN/A Sales & Book Value Annual Sales£1.32 million Price / Sales7.31 Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 4 per share Price / Book5.50Miscellaneous Outstanding Shares43,850,000Free FloatN/AMarket Cap£9.65 million OptionableNot Optionable Beta1.03 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (LON:MXC) was last updated on 10/21/2024 by MarketBeat.com Staff From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredAfter calling a 2,269% gain, here’s his NEXT tradeReady for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredCostco gold maniaIs Gold Headed Above $3,000 per Ounce? Here's How to Play It… With so many strange events happening across ...Stansberry Research | SponsoredNotice: Major payout due November 19th - are you on the list?On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's p...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredAI Detects Profit Surge On MondayThis has given investors the opportunity to beat the market by 1,700% and a 100% win rate to begin the year.Monument Traders Alliance | Sponsored[SHOCKING] Crypto Document Leak…The crypto market waits for no one. And my team of experts and I believe that a BIG move is right around th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Argent BioPharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Argent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.